In the Fred Hutch Innovation Lab, we are leading the in-house development and early adoption of powerful new research technologies that hold the potential to drive lifesaving discoveries in cancer immunology and other areas of science.
Our lab is one of the hallmarks of Fred Hutch’s Steam Plant building, a historic landmark newly redeveloped into a one-of-a-kind facility dedicated to spurring innovation at the nexus of data science and immunology.
There, we use a three-stage pipeline to develop novel technologies for use by the scientific community. First, we test, compare, advance and tailor new technologies that our Advisory Board has selected for their potential to facilitate the next discoveries in immunotherapy. Then, we work with selected researchers to evaluate the technology as they harness it to advance their early-stage research projects. Finally, we make that technology and the protocols and procedures we’ve developed available to researchers across the Hutch to accelerate their science.
Dr. Newell became the scientific director of the Fred Hutch Innovation Lab (FHIL) in January of 2022. He is an immunologist who develops and employs new technologies for accurately identifying specific biological signatures of human health and disease, including cancer and infectious diseases. He and his team work with blood and tissue samples, using mass cytometry and other single-cell analysis methods to better understand how the specificities of immune T cells influence their roles in clinically-productive responses against pathogens or cancers.
Dr. Bradley is a computational biologist who studies the 3-D structures of proteins, develops software to predict how a protein works by interacting with specific RNA and DNA sequences, and is designing proteins that might be used to make therapies work even better.
Dr. Cohn is an immunologist who uses advanced techniques to study latent HIV infections, aiming to find ways to stop the expansion and reactivation of latently infected cells, and thereby effectively cure HIV disease.
Dr. Dorer is the Vice President of Fred Hutch's Research Administration. Research Administration accelerates innovative discoveries at Fred Hutch by enabling scientific collaboration, providing opportunities and funding for enhanced cross-disciplinary interactions, making the latest technology available, and providing center-wide administrative support to our faculty and their teams.
Dr. Delrow is the Senior Director of Fred Hutch's Molecular and Cellular Scientific Resources, encompassing technologies in the areas of genomics, proteomics, flow cytometry, light and electron microscopy, and data analytics and visualization.
Dr. Furlan studies the biology of blood stem cell transplantation and cellular immunotherapy, employing a method called single-cell genomics to reveal how critical immune cells respond during these treatments and how the therapies might be further improved.
Dr. Hill is a physician-scientist who specializes in blood stem cell transplantation. He is one of the top authorities on the transplant complication known as graft-vs.-host disease, or GVHD.
Dr. Stan Riddell is a world leader in developing immunotherapies, which harness the power of the immune system to fight cancers and dangerous infections. His research focuses on detailing the complex biology of immune cells called T cells and pioneering therapies that use genetically reprogrammed T cells to specifically recognize and destroy diseased cells.